Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Metformin Shows No Significant Cardiovascular Benefits in Heart Failure Patients

2w ago August 31, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

The Met-HeFT trial and a meta-analysis revealed that metformin does not significantly reduce cardiovascular risks in heart failure patients with reduced ejection fraction and diabetes. This study was presented at the ESC Congress 2026. The findings may influence treatment protocols in Iran, where diabetes and heart disease are prevalent.

🔍 Quick Context Guide
💡 Bottom Line: The study indicates that metformin may not be a beneficial treatment for heart failure patients with diabetes, impacting clinical practices.

👥 Key Players

ESC Congress MENTIONED
Medical conference
"The European Society of Cardiology Congress is a significant event for presenting new research in cardiovascular medicine, influencing treatment protocols globally, including in Iran."
Researchers of the Met-HeFT trial MENTIONED
Conducted the study
"Their findings contribute to the understanding of diabetes and heart failure treatment, which is critical in a country like Iran where these conditions are prevalent."

📰 What Happened

The Met-HeFT trial and a meta-analysis found that metformin does not significantly reduce cardiovascular risks in heart failure patients with reduced ejection fraction and diabetes. These results were presented at the ESC Congress 2026.

  • Metformin showed no significant cardiovascular benefits for heart failure patients.
  • The study focused on patients with reduced ejection fraction and diabetes.

💡 Why It Matters

🇮🇷 For Iran: This finding may influence treatment protocols for diabetes and heart disease in Iran, where both conditions are highly prevalent.
🌍 Regional: The results could affect healthcare strategies in the Middle East, where similar health issues are common.
🌐 International: The study's findings may prompt reevaluation of metformin's role in cardiovascular treatment worldwide.

📚 Background

Heart failure and diabetes are major health concerns globally, particularly in countries like Iran where lifestyle factors contribute to high prevalence rates.

Diabetes management Cardiovascular health
📡 Source: NEUTRAL
📊 Confidence: 70%
The information is presented in a scientific context, making it reliable for understanding medical research outcomes.

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes. These were the main findings of the Met-HeFT trial and a meta-analysis presented in a Hot Line session at ESC Congress 2026.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →